+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 19 Actively Recruiting clinical trials

F

Actively Recruiting

Researchers are evaluating CT-202, a new humanized T cell engaging bispecific antibody targeting nectin-4, in people with nectin-4 positive recurrent, unresectable, or metastatic triple negative breast cancer TNBC, colorectal cancer CRC, or urothelial cancer UC that are resistant to standard treatments. This Phase 1a1b trial aims to assess the safety, tolerability, and early signs of effectiveness of CT-202. Results from this study including pharmacokinetics, pharmacodynamics, efficacy, and safety will help determine the recommended dose for future studies. The study includes two parts Phase 1a dose escalation uses a Bayesian Optimal Interval design with step-up dosing every two weeks across approximately six dose levels. Participants will continue treatment until disease progression, unacceptable side effects, withdrawal, or investigator decision. Phase 1b dose expansion will test CT-202 at two or more doses and dosing schedules across 4 to 6 groups of up to 15 participants each, focusing on the same cancer types. Data from Phase 1b will guide the recommended Phase 2 dose. Participants will undergo regular evaluations including safety monitoring and tumor assessments up to 24 months after the first dose. The main outcomes measured are dose limiting toxicities during Phase 1a and overall response rate during Phase 1b. The study includes participants aged 18 and older with measurable disease and adequate organ function. The treatment is given intravenously every two weeks, and participants are observed until disease progression or other study endpoints.

Age: 18Years +All GendersPhase 1
6 locations
S

Actively Recruiting

Researchers are evaluating whether combining pasritamig with docetaxel can extend the time before disease progression, measured by scans or death, compared to docetaxel alone in adults with metastatic castration-resistant prostate cancer. This type of prostate cancer continues to grow despite low male hormone levels. The study is a Phase 3 randomized trial designed to compare these treatments in this patient population. Participants are assigned to one of two groups. One group receives pasritamig together with docetaxel until disease progression or treatment end. The other group receives docetaxel plus prednisone or prednisolone as background medication. The study uses imaging scans and other criteria to monitor disease progression. The study treatment continues until certain protocol-defined endpoints are met. During the study, participants undergo various scans including CT, MRI, and bone scans to assess disease status. Researchers monitor progression-free survival and other outcomes such as overall survival, symptom progression, and quality of life using questionnaires. Safety is tracked by recording adverse events, lab abnormalities, and treatment side effects. Follow-up lasts up to about four and a half years, allowing comprehensive evaluation of treatment impact and safety.

Age: 18Years +All GendersPhase 3
165 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of induction therapy using Afimkibart also called RO7790121 in adults with moderately to severely active Crohns disease. This Phase III, multicenter, double-blind, placebo-controlled study aims to determine whether this treatment can induce clinical remission and improve endoscopic response compared to placebo. The trial is led by Hoffmann-La Roche and focuses on participants aged 16 to 80 years who have an inadequate response or intolerance to other Crohns disease treatments. Participants are randomly assigned to one of two groups one group receives Afimkibart initially through intravenous infusion followed by subcutaneous injections, while the other group receives a placebo intravenous infusion followed by Afimkibart subcutaneous injections. The study follows a parallel design with double-blinding to compare the effects of these treatment approaches over a 12-week induction period. During the trial, participants will undergo assessments including Crohns Disease Activity Index scoring, endoscopic evaluations, and symptom tracking such as stool consistency, abdominal pain, and fatigue. Researchers will monitor clinical remission, symptomatic relief, and adverse events up to 30 weeks after baseline. Quality of life will be measured with questionnaires, and biomarker subgroups will be analyzed. The studys total duration extends through 2033, with key measurements taken at week 12.

Age: 16Years - 80YearsAll GendersPhase 3
208 locations
R

Actively Recruiting

Researchers are evaluating whether accelerated BEP chemotherapy is more effective than standard BEP chemotherapy for males aged 11 to 50 years with intermediate and poor-risk metastatic germ cell tumors. This Phase 3 trial aims to improve cure rates for these patients since previous attempts to enhance first-line chemotherapy have been unsuccessful and more toxic. The study is sponsored by the University of Sydney and compares two chemotherapy schedules in this patient population. Participants receive either standard or accelerated BEP chemotherapy. The standard treatment involves 4 cycles every 3 weeks including bleomycin, etoposide, cisplatin, and supportive drugs like pegylated G-CSF or filgrastim, with treatment lasting about 12 weeks. The accelerated arm administers cycles every 2 weeks with similar drugs and doses but includes additional bleomycin after the 4 cycles. Dosages vary based on age and weight, and treatment is personalized by the physician. During the study, participants undergo regular assessments including response evaluations at the end of chemotherapy and at 6 months, safety monitoring for adverse events, and quality of life questionnaires up to 18 months. Researchers measure progression-free survival and overall survival for up to 5 years. The trial involves randomized assignment to treatment groups and careful monitoring of chemotherapy dosing and patient health throughout the study period.

Age: 11Years - 50YearsAll GendersPhase 3
56 locations
S

Actively Recruiting

Researchers are conducting a combined phase 2b and phase 3 clinical trial to study CSL300 Clazakizumab in adults with end stage kidney disease ESKD who are undergoing maintenance dialysis. The study aims to find the right dose of CSL300 and then evaluate its effects on cardiovascular outcomes and safety in people with systemic inflammation and either atherosclerotic cardiovascular disease ASCVD or diabetes. This multicenter, randomized, double-blind, placebo-controlled trial is designed to provide detailed information on the drugs impact and risks. The study is divided into two parts. Part 1 phase 2b focuses on identifying the optimal dose of CSL300 compared to a placebo over 12 weeks. Part 2 phase 3 assesses the efficacy and safety of CSL300 versus placebo on cardiovascular events such as cardiovascular death or heart attack over approximately 5 years. Participants receive intravenous doses of CSL300 or placebo. The placebo matches the CSL300 product minus the active ingredient. Participants will be monitored through regular assessments including blood tests to measure markers of inflammation like high-sensitivity C-reactive protein hs-CRP, other blood components, and drug levels. The trial tracks cardiovascular events and safety outcomes over the study period. The research team will also observe changes in several blood markers related to inflammation and cardiovascular health. The total follow-up may last up to about five years to fully capture long-term effects and safety.

Age: 18Years +All GendersPhase 2Phase 3
566 locations
P

Actively Recruiting

Researchers are evaluating DCSZ11, a monoclonal antibody, as a treatment for patients with advanced or metastatic solid tumors. This Phase 1, multicenter, open-label study aims to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and potential antitumor activity of DCSZ11 both alone and in combination with pembrolizumab. The study includes patients who have relapsed or refractory tumors and have limited or no effective standard therapy options. The study has two main phases Phase 1a Dose Escalation and Phase 1b Dose ExpansionOptimization. In Phase 1a, patients receive intravenous infusions of DCSZ11 every 3 weeks either as monotherapy or combined with pembrolizumab, with doses increased to find the maximum tolerated or planned dose. Phase 1b evaluates DCSZ11 combined with pembrolizumab or standard-of-care treatments like doxorubicin for soft tissue sarcoma and tebentafusp for uveal melanoma, using designs to optimize dosing and monitor safety continuously. Participants will undergo screening that includes biopsies, imaging, and laboratory tests to confirm eligibility and monitor response. Researchers will evaluate tumor response using established criteria such as RECIST and iRECIST over one year, and follow safety and survival outcomes for up to three years. The study involves regular clinic visits, safety assessments, and monitoring for immune responses and drug levels to understand treatment effects and tolerability.

Age: 18Years +All GendersPhase 1
35 locations
P

Actively Recruiting

Researchers are evaluating the preliminary efficacy, safety, and population pharmacokinetics PopPK of ABP-745 in adults aged 18 to 75 years who have atherosclerotic cardiovascular disease ASCVD. This randomized, double-blind, placebo-controlled Phase II study aims to compare the ability of ABP-745 to reduce atherosclerotic plaque against a placebo. The primary measurement of efficacy will be the change in percent atheroma volume PAV after 52 weeks of treatment. Participants will be randomly assigned to one of four groups placebo or one of three different doses of ABP-745 tablets taken orally once daily. Throughout the study, existing lipid-lowering maintenance medications will remain unchanged. The study includes a 52-week treatment period, after which the primary outcome will be assessed. Safety and tolerability will also be monitored up to 14 days after the last dose. During the study, participants will continue their current oral lipid-lowering therapy and attend regular visits for assessments including physical exams, vital signs, laboratory tests, and ECGs. Researchers will measure changes in atherosclerotic plaque volume and monitor for adverse events. The total duration of participation includes the 52-week treatment period plus safety follow-up, with detailed monitoring to evaluate the impact and safety of ABP-745 in this population.

Age: 18Years - 75YearsAll GendersPhase 2
33 locations
A

Actively Recruiting

Researchers are evaluating the safety and effectiveness of intravesical administration of detalimogene EG-70, a novel non-viral gene therapy, in patients with non-muscle invasive bladder cancer NMIBC. The study focuses on patients with carcinoma in situ CIS unresponsive to BCG therapy and other high-risk NMIBC patients, including those who are BCG-nafve or incompletely treated. The trial includes a Phase 1 dose-escalation to determine safety and recommended dose, followed by a Phase 2 to assess treatment effectiveness. Participants will receive EG-70 via bladder instillation with a catheter in cycles lasting about 12 weeks. Phase 1 involves up to four cycles with either two or four doses per cycle, aiming for a 60-minute retention time. Phase 2 participants receive four instillations per cycle for up to four cycles at the recommended dose. Those achieving complete response may continue with maintenance treatment involving two doses per 12-week cycle. A substudy includes a surfactant bladder rinse before EG-70 instillation, with a shortened administration time. During the study, participants undergo regular assessments including cystoscopy, urine cytology, and biopsies to monitor response and safety. Researchers track adverse events, treatment response rates, duration of response, progression-free survival, and quality of life over periods ranging from weeks to years. Safety monitoring follows standardized criteria, and participants may continue in maintenance cycles if responding. The total study duration extends up to approximately nine years from start to completion.

Age: 18Years +All GendersPhase 1Phase 2
102 locations
E

Actively Recruiting

Researchers are evaluating the safety, tolerability, and effectiveness of N-3C01, given as a subcutaneous injection, either alone or combined with a PD-L1 monoclonal antibody, in adults with advanced malignant solid tumors. This Phase III study includes a dose escalation phase for both monotherapy and combination therapy, followed by a cohort expansion phase for the combination treatment. Participants will receive N-3C01 injections every 2 or 3 weeks. Some participants with selected tumor types will also receive pembrolizumab, an intravenous PD-L1 monoclonal antibody, alongside N-3C01. During Phase I, different doses and schedules will be tested to find the maximum tolerated dose and recommended Phase II dose. In Phase II, participants will receive the recommended dose of N-3C01 combined with a fixed dose of the PD-L1 antibody. Participants will be closely monitored through safety assessments including vital signs, ECGs, blood tests, and urinalysis up to about 24 months. Researchers will track adverse events, dose-limiting toxicities, and treatment effects on tumors. Pharmacokinetics and immune responses will also be measured. The study involves regular visits for treatment and safety follow-up to ensure thorough monitoring throughout the trial.

Age: 18Years - 75YearsAll GendersPhase 1Phase 2
6 locations
E

Actively Recruiting

Researchers are evaluating a new way to deliver treatment using the ECAP-controlled closed-loop spinal cord stimulation SCS system called the Evoke System. This study focuses on patients who experience chronic pain in the trunk andor limbs. The goal is to test and assess new software and hardware features that may improve how the Evoke System delivers treatment. Participants will use the Evoke Spinal Cord Stimulation System, which measures electrical activity called evoked compound action potentials ECAPs. The device automatically adjusts the stimulation current to keep the ECAP amplitude consistent. This study involves a single group of participants using this novel device and will continue through to study completion, which may last up to two years. During the study, participants will be monitored for changes in ECAPs measured by the Evoke System. Researchers will evaluate these changes over the course of the study to understand how the device functions with the new features. Participants will need to provide informed consent and comply with study requirements while using the device. The total participation time can last up to two years, with regular assessments conducted throughout this period.

Age: 18Years +All GendersPhase Not Applicable
25 locations

1-10 of 19

1